ACoP15 2024 Blog Post
Thank you Page
Thank you Thank you for requesting a demo of Market Access Radar. We will be in touch soon. You May Also Like AllMarket Access & Commercial Critical Roles for Modeling...Thank you Page
Thank you for requesting a free trial of Market Access Radar. We will be in contact soon.
Thank you Page
Thank you Thank you for registering for our event. You May Also Like AllConference EACPT 2025 CONGRESSEACPT 2025 CONGRESSConferenceEACPT 2025 CONGRESS PSI 2025 ConferencePSI 2025 ConferenceConferencePSI 2025 Conference 2025 Korea...Subscribed Page
Subscribed Thank you for subscribing to our content We look forward to sharing new insights on transforming drug development and pushing the boundaries of science with you. ケーススタディを読む{{i:1}}...Confirmation Page
Confirmation Thank you for contacting us about Project Optimus. We will be in contact shortly. You May Also Like AllProject Optimus Using Quantitative Systems Pharmacology (QSP) Modeling for Oncology Dose...
Dose Optimization: Getting it Right for Vulnerable Populations Blog Post
By: Justin Hay & Frank Engler Pandemics amplify existing strengths and vulnerabilities—not only highlighting who are among the at-risk populations in our society, but also bringing to prominence strengths and…
Japan’s Approach to Pediatric Drug Development: What You Need to Know Blog Post
安全性と有効性に優れた治療薬へのアクセスは⼩児患者にとって⾮常に深刻な問題です。小児に処方される医薬品の60～70％は適応外使用なのが現実です。In Japan, only 30% of new drugs are approved for…
Certara’s Synchrogenix Writer now enhanced with AI Layar Blog Post
Next generation automation for Medical Writers to streamline the creation of regulatory documents Certara is excited to announce that SynchrogenixTM Writer is the latest Certara software to incorporate powerful deep…
